EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models

Jezabel Rodriguez-Blanco, April D Salvador, Robert K Suter, Marzena Swiderska-Syn, Isabel Palomo-Caturla, Valentin Kliebe, Pritika Shahani, Kendell Peterson, Maria Turos-Cabal, Megan E Vieira, Daniel T Wynn, Ashley J Howell und 16 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci171136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jezabel Rodriguez-Blanco und 27 weiteren Autor:innen. Beteiligte Einrichtung: Darby Children's Research Institute, Department of Pediatrics, and. Hauptthemen laut MEDLINE: Phenanthrenes, Diterpenes, Epoxy Compounds, Medulloblastoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, Rally Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most children with medulloblastoma (MB) achieve remission, but some face very aggressive metastatic tumors. Their dismal outcome highlights the critical need to advance therapeutic approaches that benefit such high-risk patients. Minnelide, a clinically relevant analog of the natural product triptolide, has oncostatic activity in both preclinical and early clinical settings. Despite its efficacy and tolerable toxicity, this compound has not been evaluated in MB. Utilizing a bioinformatic data set that integrates cellular drug response data with gene expression, we predicted that Group 3 (G3) MB, which has a poor 5-year survival, would be sensitive to triptolide/Minnelide. We subsequently showed that both triptolide and Minnelide attenuate the viability of G3 MB cells ex vivo. Transcriptomic analyses identified MYC signaling, a pathologically relevant driver of G3 MB, as a downstream target of this class of drugs. We validated this MYC dependency in G3 MB cells and showed that triptolide exerts its efficacy by reducing both MYC transcription and MYC protein stability. Importantly, Minnelide acted on MYC to reduce tumor growth and leptomeningeal spread, which resulted in improved survival of G3 MB animal models. Moreover, Minnelide improved the efficacy of adjuvant chemotherapy, further highlighting its potential for the treatment of MYC-driven G3 MB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenanthrenesDiterpenesEpoxy CompoundsMedulloblastomaProto-Oncogene Proteins c-mycXenograft Model Antitumor AssaysAnimalsHumansMiceCell Line, TumorProdrugsCerebellar NeoplasmsFemaleGene Expression Regulation, NeoplasticOrganophosphates

Stichwörter der Autor:innen

Brain cancerOncology

Substanzen

PhenanthrenesDiterpenestriptolideEpoxy CompoundsProto-Oncogene Proteins c-myc14-O-phosphonooxymethyltriptolide disodium saltMYC protein, humanProdrugsOrganophosphates

Autor:innen und Institutionen

  • Darby Children's Research Institute, Department of Pediatrics, and.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA.
  • Department of Public Health Sciences, and.
  • Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
  • Departments of Neurological Surgery and Pediatrics, University of Miami, Jackson Health System, Miller School of Medicine, Miami, Florida, USA.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • Rally Foundation
  • V Foundation for Cancer Research
  • Vince Lombardi Cancer Foundation
  • Monka Foundation
  • American Cancer Society
  • National Cancer Institute

Zitieren

APA

Rodriguez-Blanco, J., Salvador, A. D., Suter, R. K., Swiderska-Syn, M., Palomo-Caturla, I., Kliebe, V., Shahani, P., Peterson, K., Turos-Cabal, M., Vieira, M. E., Wynn, D. T., Howell, A. J., Yang, F., Ban, Y., McCrea, H. J., Zindy, F., Danis, E., Vibhakar, R., Jermakowicz, A., …, & Robbins, D. J. (2024). Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. Journal of Clinical Investigation. https://doi.org/10.1172/jci171136

Vancouver

Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, et al. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. Journal of Clinical Investigation. 2024. doi:10.1172/jci171136

BibTeX
@article{RodriguezBlanco2024,
  author = {Rodriguez-Blanco, Jezabel and Salvador, April D and Suter, Robert K and Swiderska-Syn, Marzena and Palomo-Caturla, Isabel and Kliebe, Valentin and Shahani, Pritika and Peterson, Kendell and Turos-Cabal, Maria and Vieira, Megan E and Wynn, Daniel T and Howell, Ashley J and Yang, Fan and Ban, Yuguang and McCrea, Heather J and Zindy, Frederique and Danis, Etienne and Vibhakar, Rajeev and Jermakowicz, Anna and Martin, Vanesa and Coss, Christopher C and Harris, Brent T and de Cubas, Aguirre and Chen, X Steven and Barnoud, Thibaut and Roussel, Martine F and Ayad, Nagi G and Robbins, David J},
  title = {Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci171136}
}
Kostenlos starten →